JP2012500806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500806A5 JP2012500806A5 JP2011524060A JP2011524060A JP2012500806A5 JP 2012500806 A5 JP2012500806 A5 JP 2012500806A5 JP 2011524060 A JP2011524060 A JP 2011524060A JP 2011524060 A JP2011524060 A JP 2011524060A JP 2012500806 A5 JP2012500806 A5 JP 2012500806A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- formula
- item
- items
- cation exchange
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims description 323
- 239000000203 mixture Substances 0.000 claims description 115
- 238000005341 cation exchange Methods 0.000 claims description 74
- 239000000178 monomer Substances 0.000 claims description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims description 56
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 50
- 239000011591 potassium Substances 0.000 claims description 50
- 229910052700 potassium Inorganic materials 0.000 claims description 50
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 47
- 238000006116 polymerization reaction Methods 0.000 claims description 35
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 27
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 25
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 22
- 125000001033 ether group Chemical group 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 18
- 125000002947 alkylene group Chemical group 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 150000003839 salts Chemical group 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000000732 arylene group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 239000003505 polymerization initiator Substances 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 230000003301 hydrolyzing effect Effects 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- -1 propylene, butylene, pentylene Chemical group 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920006037 cross link polymer Polymers 0.000 claims description 3
- 229910001414 potassium ion Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 description 20
- 229920005862 polyol Polymers 0.000 description 20
- 150000003077 polyols Chemical class 0.000 description 20
- 150000001408 amides Chemical group 0.000 description 16
- 150000002431 hydrogen Chemical group 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 5
- 239000005541 ACE inhibitor Substances 0.000 description 4
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 4
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 208000002682 Hyperkalemia Diseases 0.000 description 4
- 229940083712 aldosterone antagonist Drugs 0.000 description 4
- 239000002170 aldosterone antagonist Substances 0.000 description 4
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 4
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012798 spherical particle Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000005480 Olmesartan Substances 0.000 description 2
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 2
- NRTXADDPBIKAKB-UHFFFAOYSA-L calcium;2-fluoroprop-2-enoate Chemical compound [Ca+2].[O-]C(=O)C(F)=C.[O-]C(=O)C(F)=C NRTXADDPBIKAKB-UHFFFAOYSA-L 0.000 description 2
- 229960000932 candesartan Drugs 0.000 description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- 229960004563 eprosartan Drugs 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 229960002490 fosinopril Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229960002198 irbesartan Drugs 0.000 description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960005117 olmesartan Drugs 0.000 description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
- 229960002582 perindopril Drugs 0.000 description 2
- 229960001455 quinapril Drugs 0.000 description 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
- 229960003401 ramipril Drugs 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- 229960002769 zofenopril Drugs 0.000 description 2
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 2
- 0 *C(I)=C(*=C)F Chemical compound *C(I)=C(*=C)F 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical group S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9112508P | 2008-08-22 | 2008-08-22 | |
| US9111008P | 2008-08-22 | 2008-08-22 | |
| US9109708P | 2008-08-22 | 2008-08-22 | |
| US61/091,125 | 2008-08-22 | ||
| US61/091,110 | 2008-08-22 | ||
| US61/091,097 | 2008-08-22 | ||
| US16589909P | 2009-04-01 | 2009-04-01 | |
| US16589409P | 2009-04-01 | 2009-04-01 | |
| US61/165,899 | 2009-04-01 | ||
| US61/165,894 | 2009-04-01 | ||
| US16590509P | 2009-04-02 | 2009-04-02 | |
| US61/165,905 | 2009-04-02 | ||
| PCT/US2009/054706 WO2010022383A2 (en) | 2008-08-22 | 2009-08-22 | Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014098678A Division JP2014144978A (ja) | 2008-08-22 | 2014-05-12 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2014098677A Division JP5883471B2 (ja) | 2008-08-22 | 2014-05-12 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012500806A JP2012500806A (ja) | 2012-01-12 |
| JP2012500806A5 true JP2012500806A5 (https=) | 2012-10-11 |
| JP5756403B2 JP5756403B2 (ja) | 2015-07-29 |
Family
ID=41707686
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011524060A Active JP5756403B2 (ja) | 2008-08-22 | 2009-08-22 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2014098677A Active JP5883471B2 (ja) | 2008-08-22 | 2014-05-12 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2014098678A Withdrawn JP2014144978A (ja) | 2008-08-22 | 2014-05-12 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2016095867A Active JP6232468B2 (ja) | 2008-08-22 | 2016-05-12 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2017181132A Active JP6633583B2 (ja) | 2008-08-22 | 2017-09-21 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2018238997A Active JP6890116B2 (ja) | 2008-08-22 | 2018-12-21 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2020119093A Withdrawn JP2020172537A (ja) | 2008-08-22 | 2020-07-10 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014098677A Active JP5883471B2 (ja) | 2008-08-22 | 2014-05-12 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2014098678A Withdrawn JP2014144978A (ja) | 2008-08-22 | 2014-05-12 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2016095867A Active JP6232468B2 (ja) | 2008-08-22 | 2016-05-12 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2017181132A Active JP6633583B2 (ja) | 2008-08-22 | 2017-09-21 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2018238997A Active JP6890116B2 (ja) | 2008-08-22 | 2018-12-21 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
| JP2020119093A Withdrawn JP2020172537A (ja) | 2008-08-22 | 2020-07-10 | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20110236340A1 (https=) |
| EP (4) | EP4201408B1 (https=) |
| JP (7) | JP5756403B2 (https=) |
| KR (5) | KR102178208B1 (https=) |
| CN (2) | CN102202670B (https=) |
| AU (1) | AU2009282721B2 (https=) |
| BR (1) | BRPI0917853C1 (https=) |
| CA (1) | CA2735058C (https=) |
| CY (3) | CY2018002I1 (https=) |
| DE (1) | DE112009002063T5 (https=) |
| DK (3) | DK2957286T3 (https=) |
| ES (4) | ES2699494T3 (https=) |
| FI (1) | FI3431094T3 (https=) |
| GB (4) | GB2495427B (https=) |
| HR (4) | HRP20230091T1 (https=) |
| HU (4) | HUE025934T2 (https=) |
| LT (4) | LT3431094T (https=) |
| LU (1) | LUC00094I2 (https=) |
| MX (3) | MX389664B (https=) |
| NL (1) | NL300962I2 (https=) |
| NO (2) | NO2018004I1 (https=) |
| PL (4) | PL2365988T5 (https=) |
| PT (3) | PT2365988E (https=) |
| SI (2) | SI3431094T1 (https=) |
| SM (2) | SMT201800660T1 (https=) |
| WO (1) | WO2010022383A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8574716B2 (en) * | 2006-01-23 | 2013-11-05 | Hitachi Chemical Co., Ltd. | Ionic polymer devices and methods of fabricating the same |
| PT2365988E (pt) | 2008-08-22 | 2015-10-22 | Relypsa Inc | Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia |
| US8337824B2 (en) | 2008-08-22 | 2012-12-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
| KR101839038B1 (ko) * | 2010-03-20 | 2018-03-16 | 리립사, 인크. | 폴리플루오로아크릴레이트 입자를 제조하기 위한 연속식 방법 |
| SI2673237T2 (sl) | 2011-02-11 | 2025-12-31 | Zs Pharma, Inc | Uporaba cirkonijevega silikata v zdravljenju hiperkalemije |
| ES2895909T3 (es) | 2011-06-27 | 2022-02-23 | Vifor Pharma Tech Ltd | Procedimiento para la conversión de un éster polimérico a un ácido polimérico |
| RU2619108C2 (ru) | 2011-06-27 | 2017-05-12 | Релипса, Инк. | Фторирование эфиров акриловой кислоты и их производных |
| CA2879425A1 (en) * | 2012-07-19 | 2014-01-23 | Relypsa, Inc. | Compositions comprising crosslinked cation-binding polymers |
| WO2014023826A1 (en) * | 2012-08-09 | 2014-02-13 | Dsm Ip Assets B.V. | Process for drying polymeric materials |
| KR20210005314A (ko) * | 2012-10-08 | 2021-01-13 | 리립사, 인크. | 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제 |
| US10695365B2 (en) | 2012-10-22 | 2020-06-30 | ZS Pharma, Inc. | Microporous zirconium silicate for the treatment of hyperkalemia |
| BR112015025438B1 (pt) | 2013-04-05 | 2022-06-07 | Zs Pharma, Inc | Uso de um silicato de zircônio |
| EP3236940B1 (en) * | 2014-12-23 | 2020-02-05 | Ardelyx, Inc. | Compositions and methods for treating hyperkalemia |
| DE112016003948T5 (de) | 2015-08-31 | 2018-05-09 | City Of Sapporo | Molekulare verfahren zum beurteilen einer urothelialen erkrankung |
| US9592253B1 (en) | 2015-10-14 | 2017-03-14 | ZS Pharma, Inc. | Extended use zirconium silicate compositions and methods of use thereof |
| ITUB20159278A1 (it) | 2015-12-23 | 2017-06-23 | Rjw Pharma Llc | Procedimento per la sintesi di patiromer |
| WO2019220450A1 (en) | 2018-05-16 | 2019-11-21 | Solara Active Pharma Sciences Limited | Process for preparation of patiromer |
| BR112021017791A2 (pt) * | 2019-03-13 | 2022-02-01 | Astrazeneca Ab | Agentes de ligação ao potássio para uso em pacientes em hemodiálise |
| WO2021097012A1 (en) * | 2019-11-14 | 2021-05-20 | Relypsa, Inc. | One step synthesis for alkyl 2-fluoroacrylates |
| WO2021191876A1 (en) | 2020-03-27 | 2021-09-30 | Vifor (International) Ltd. | Synthesis of methyl 2-fluoroacrylate |
| CN116323717A (zh) * | 2021-09-13 | 2023-06-23 | 中美华世通生物医药科技(武汉)股份有限公司 | 治疗高钾血症的聚合物药物及其制备方法 |
| US20240139234A1 (en) * | 2021-11-17 | 2024-05-02 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Pharmaceutical polymer for treating hyperkalemia and preparation method thereof |
| CN114369729B (zh) * | 2021-12-28 | 2023-11-03 | 江苏容汇通用锂业股份有限公司 | 一种利用锂矿渣进行浸出液除钾的工艺 |
| CN114394918B (zh) * | 2022-01-19 | 2023-10-20 | 罗长青 | 一种2-[[三(羟甲基)甲基]氨基]乙磺酸的制备方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2611730A (en) * | 1950-09-02 | 1952-09-23 | Simth Kline & French Lab | Medical preparation for reducing the body level of sodium |
| US2909462A (en) * | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US3499960A (en) * | 1965-01-25 | 1970-03-10 | Merck & Co Inc | Palatable coated particles of an anion exchange resin |
| NL137053C (https=) | 1967-01-30 | |||
| FR2171934B1 (https=) * | 1972-02-16 | 1974-09-13 | Rhone Poulenc Sa | |
| US3974272A (en) * | 1972-09-01 | 1976-08-10 | Merck & Co., Inc. | Palatable cholestyramine coacervate compositions |
| US4143130A (en) * | 1977-08-29 | 1979-03-06 | Warren-Teed Laboratories, Inc. | Method for treating kidney stones |
| US4470975A (en) * | 1977-10-21 | 1984-09-11 | The Johns Hopkins University | Method and composition for the elimination of water from an animal body |
| US4380590A (en) * | 1978-09-19 | 1983-04-19 | Rohm And Haas Company | Emulsion copolymer cation exchange resins |
| DE2846187A1 (de) | 1978-10-24 | 1980-05-08 | Bayer Ag | Kunstharze auf basis vernetzter mischpolymerisate aus mono- und polyvinylverbindungen |
| JPS6090243A (ja) * | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
| US4747881A (en) * | 1985-02-05 | 1988-05-31 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
| US5186937A (en) * | 1985-06-07 | 1993-02-16 | A.E.C. Societe De Chimie Organique Et Biologique | Composition for feeding ruminants |
| IT1190349B (it) * | 1986-06-16 | 1988-02-16 | Prodotti Formenti Srl | Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle |
| JPS63218713A (ja) * | 1987-02-17 | 1988-09-12 | Daikin Ind Ltd | α−フルオロアクリル酸系重合体ならびに用途 |
| US4837015A (en) * | 1987-03-05 | 1989-06-06 | Carolina Medical Products Company, Inc. | Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels |
| GB8817015D0 (en) * | 1988-07-16 | 1988-08-17 | Reckitt & Colmann Prod Ltd | Method of treatment |
| GB8829088D0 (en) † | 1988-12-13 | 1989-01-25 | Smith Kline French Lab | Compounds |
| US5236701A (en) * | 1989-07-19 | 1993-08-17 | Lowchol Scientific Inc. | Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol |
| DE3928990A1 (de) | 1989-09-01 | 1991-03-07 | Bayer Ag | Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten |
| US5112993A (en) | 1989-11-14 | 1992-05-12 | E. I. Du Pont De Nemours And Company | Process for the preparation of difluoromaleic anhydride |
| US5091175A (en) * | 1990-05-14 | 1992-02-25 | Erbamont Inc. | Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane |
| DE69016014T2 (de) * | 1990-07-04 | 1995-08-31 | Marcin Krotkiewski | Blutdrucksenkendes Präparat. |
| US5162110A (en) * | 1990-12-19 | 1992-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Binding theophylline to ion exchange resins |
| US5281631A (en) * | 1991-12-20 | 1994-01-25 | Arch Development Corp. | Phosphonic acid based ion exchange resins |
| EP0565086B1 (en) | 1992-04-10 | 1996-12-27 | Mitsubishi Chemical Corporation | Method for producing a spherical acrylonitrile crosslinked copolymer |
| ATE168707T1 (de) * | 1992-08-20 | 1998-08-15 | Du Pont | Vernetzte polymerische ammoniumsalze |
| US5487888A (en) * | 1993-05-20 | 1996-01-30 | Geltex, Inc. | Iron-binding polymers for oral administration |
| US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
| US5618530A (en) * | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
| US5667775A (en) * | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| WO1995014531A1 (en) * | 1993-11-25 | 1995-06-01 | Salternate B.V. | Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions |
| TW474813B (en) * | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| US5824339A (en) * | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
| US6623759B2 (en) * | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| US5935599A (en) * | 1996-10-28 | 1999-08-10 | The Board Of Trustees Of The University Of Illinois | Polymer-associated liposomes for drug delivery and method of manufacturing the same |
| KR100440544B1 (ko) * | 1998-07-31 | 2004-07-15 | 니켄 가가쿠 가부시키가이샤 | 양이온 교환수지 제제 |
| US6294163B1 (en) * | 1998-10-02 | 2001-09-25 | Geltex Pharmaceuticals, Inc. | Polymers containing guanidinium groups as bile acid sequestrants |
| US6558665B1 (en) * | 1999-05-18 | 2003-05-06 | Arch Development Corporation | Encapsulating particles with coatings that conform to size and shape of the particles |
| US6733780B1 (en) * | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| US20020054903A1 (en) * | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
| DE19951116A1 (de) | 1999-10-23 | 2001-04-26 | Bosch Gmbh Robert | Relais, insbesondere für eine Startvorrichtung |
| DE19962935A1 (de) † | 1999-12-24 | 2001-06-28 | Bayer Ag | Verfahren zur Herstellung von vernetzten Ionenaustauschern auf Basis von ungesättigten, aliphatischen Nitrilen |
| CA2396915A1 (en) * | 2000-01-14 | 2001-07-19 | Otsuka Pharmaceutical Factory, Inc. | Sodium ion absorption inhibitors, and preventive and therapeutic agents and foods containing the same |
| US6994827B2 (en) | 2000-06-03 | 2006-02-07 | Symyx Technologies, Inc. | Parallel semicontinuous or continuous reactors |
| JP4873824B2 (ja) * | 2000-08-01 | 2012-02-08 | オリザ油化株式会社 | 糖質吸収阻害剤およびその製造方法 |
| AU2002232955A1 (en) * | 2000-11-20 | 2002-05-27 | Dow Global Technologies Inc. | In vivo use of water absorbent polymers |
| US7033639B2 (en) * | 2001-05-16 | 2006-04-25 | Rohm And Haas Company | Polyaniline coating composition |
| US6881484B2 (en) * | 2001-05-30 | 2005-04-19 | Mitsubishi Kagaku Iatron, Inc. | Core-shell particle including signal-generating substance enclosed therein and process for producing the same |
| CA2516457C (en) * | 2003-02-25 | 2011-12-06 | Finnfeeds Finland Oy | A simulated moving bed system and process |
| US7381428B2 (en) | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
| US8192758B2 (en) * | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
| US8282960B2 (en) * | 2004-03-30 | 2012-10-09 | Relypsa, Inc. | Ion binding compositions |
| US7854924B2 (en) * | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| US7429394B2 (en) * | 2004-03-30 | 2008-09-30 | Relypsa, Inc. | Ion binding compositions |
| BRPI0509365B8 (pt) * | 2004-03-30 | 2021-05-25 | Ilypsa Inc | composição farmacêutica, kit farmacêutico, e, uso da referida composição |
| US7556799B2 (en) * | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
| WO2007038801A2 (en) | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof |
| BRPI0616603A2 (pt) * | 2005-09-30 | 2012-12-25 | Ilypsa Inc | mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma |
| WO2007041569A1 (en) * | 2005-09-30 | 2007-04-12 | Ilypsa, Inc. | Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal |
| AU2008292907A1 (en) * | 2007-08-29 | 2009-03-05 | Sorbent Therapeutics, Inc. | Absorbent polymeric compositions with varying counterion content and their methods of preparation and use |
| WO2010022381A1 (en) * | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| US8337824B2 (en) * | 2008-08-22 | 2012-12-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
| US20100111892A1 (en) * | 2008-08-22 | 2010-05-06 | Relypsa, Inc. | Crosslinked polyfluoroacrylic acid and processes for the preparation thereof |
| PT2365988E (pt) | 2008-08-22 | 2015-10-22 | Relypsa Inc | Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia |
-
2009
- 2009-08-22 PT PT97485577T patent/PT2365988E/pt unknown
- 2009-08-22 ES ES15171701T patent/ES2699494T3/es active Active
- 2009-08-22 EP EP22211737.6A patent/EP4201408B1/en active Active
- 2009-08-22 HU HUE09748557A patent/HUE025934T2/en unknown
- 2009-08-22 HR HRP20230091TT patent/HRP20230091T1/hr unknown
- 2009-08-22 GB GB1222750.0A patent/GB2495427B/en active Active
- 2009-08-22 CN CN200980137593.3A patent/CN102202670B/zh active Active
- 2009-08-22 DK DK15171701.4T patent/DK2957286T3/en active
- 2009-08-22 EP EP18188764.7A patent/EP3431094B1/en active Active
- 2009-08-22 SM SM20180660T patent/SMT201800660T1/it unknown
- 2009-08-22 GB GB1104561.4A patent/GB2475657B/en active Active
- 2009-08-22 FI FIEP18188764.7T patent/FI3431094T3/fi active
- 2009-08-22 ES ES22211737T patent/ES3034535T3/es active Active
- 2009-08-22 PL PL09748557T patent/PL2365988T5/pl unknown
- 2009-08-22 AU AU2009282721A patent/AU2009282721B2/en active Active
- 2009-08-22 DE DE112009002063T patent/DE112009002063T5/de not_active Ceased
- 2009-08-22 HR HRP20150955TT patent/HRP20150955T1/hr unknown
- 2009-08-22 EP EP15171701.4A patent/EP2957286B1/en active Active
- 2009-08-22 SI SI200932178T patent/SI3431094T1/sl unknown
- 2009-08-22 KR KR1020207006869A patent/KR102178208B1/ko active Active
- 2009-08-22 CN CN201410106433.5A patent/CN103919792B/zh active Active
- 2009-08-22 PL PL15171701T patent/PL2957286T3/pl unknown
- 2009-08-22 US US13/060,207 patent/US20110236340A1/en not_active Abandoned
- 2009-08-22 EP EP09748557.7A patent/EP2365988B2/en active Active
- 2009-08-22 KR KR1020187002772A patent/KR101928973B1/ko active Active
- 2009-08-22 MX MX2019004453A patent/MX389664B/es unknown
- 2009-08-22 MX MX2011001893A patent/MX2011001893A/es active IP Right Grant
- 2009-08-22 DK DK18188764.7T patent/DK3431094T3/da active
- 2009-08-22 KR KR1020187035573A patent/KR102150184B1/ko active Active
- 2009-08-22 CA CA2735058A patent/CA2735058C/en active Active
- 2009-08-22 PL PL22211737.6T patent/PL4201408T3/pl unknown
- 2009-08-22 LT LTEP18188764.7T patent/LT3431094T/lt unknown
- 2009-08-22 BR BRPI0917853A patent/BRPI0917853C1/pt active IP Right Grant
- 2009-08-22 PT PT15171701T patent/PT2957286T/pt unknown
- 2009-08-22 LT LTEP15171701.4T patent/LT2957286T/lt unknown
- 2009-08-22 MX MX2015000657A patent/MX364398B/es unknown
- 2009-08-22 HU HUE18188764A patent/HUE061320T2/hu unknown
- 2009-08-22 JP JP2011524060A patent/JP5756403B2/ja active Active
- 2009-08-22 HR HRP20250774TT patent/HRP20250774T1/hr unknown
- 2009-08-22 HU HUE22211737A patent/HUE071829T2/hu unknown
- 2009-08-22 SI SI200931889T patent/SI2957286T1/sl unknown
- 2009-08-22 ES ES09748557T patent/ES2545887T5/es active Active
- 2009-08-22 ES ES18188764T patent/ES2939021T3/es active Active
- 2009-08-22 DK DK09748557.7T patent/DK2365988T4/da active
- 2009-08-22 PT PT181887647T patent/PT3431094T/pt unknown
- 2009-08-22 PL PL18188764.7T patent/PL3431094T3/pl unknown
- 2009-08-22 WO PCT/US2009/054706 patent/WO2010022383A2/en not_active Ceased
- 2009-08-22 KR KR1020117006635A patent/KR101825113B1/ko not_active Expired - Fee Related
- 2009-08-22 KR KR1020207032030A patent/KR102300471B1/ko not_active Expired - Fee Related
-
2012
- 2012-12-17 GB GB1222752.6A patent/GB2495428A/en not_active Withdrawn
- 2012-12-17 GB GB1222749.2A patent/GB2495426A/en not_active Withdrawn
-
2014
- 2014-05-12 JP JP2014098677A patent/JP5883471B2/ja active Active
- 2014-05-12 JP JP2014098678A patent/JP2014144978A/ja not_active Withdrawn
-
2015
- 2015-09-02 SM SM201500207T patent/SMT201500207T1/xx unknown
-
2016
- 2016-05-12 JP JP2016095867A patent/JP6232468B2/ja active Active
-
2017
- 2017-02-27 US US15/443,664 patent/US20170165292A1/en not_active Abandoned
- 2017-09-21 JP JP2017181132A patent/JP6633583B2/ja active Active
-
2018
- 2018-01-15 CY CY2018002C patent/CY2018002I1/el unknown
- 2018-01-15 LT LTPA2018004C patent/LTPA2018004I1/lt unknown
- 2018-01-17 NO NO2018004C patent/NO2018004I1/no unknown
- 2018-11-22 HR HRP20181961TT patent/HRP20181961T1/hr unknown
- 2018-11-29 CY CY20181101268T patent/CY1120930T1/el unknown
- 2018-12-13 LT LTPA2018016 patent/LTC2957286I2/lt unknown
- 2018-12-13 LU LU00094C patent/LUC00094I2/fr unknown
- 2018-12-14 NL NL300962C patent/NL300962I2/nl unknown
- 2018-12-14 NO NO2018041C patent/NO2018041I1/no unknown
- 2018-12-21 JP JP2018238997A patent/JP6890116B2/ja active Active
-
2019
- 2019-01-09 CY CY2019002C patent/CY2019002I1/el unknown
- 2019-01-15 HU HUS1900003C patent/HUS1900003I1/hu unknown
- 2019-11-01 US US16/672,005 patent/US20200289550A1/en not_active Abandoned
-
2020
- 2020-07-10 JP JP2020119093A patent/JP2020172537A/ja not_active Withdrawn
-
2021
- 2021-05-18 US US17/323,627 patent/US20220000906A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500806A5 (https=) | ||
| JP2017218454A5 (https=) | ||
| JP6817185B2 (ja) | 高血圧症及び高カリウム血症を治療するためのカリウム結合剤 | |
| JP5756403B2 (ja) | 架橋陽イオン交換ポリマー、組成物、および高カリウム血症の治療における使用 | |
| JP2026053537A (ja) | Ｎｈｅ３結合化合物およびリン酸輸送の阻害方法 | |
| JPWO2009008480A1 (ja) | 架橋ポリアリルアミン又はその酸付加塩、及びその医薬用途 | |
| IT202000016639A1 (it) | Composizione per uso nel trattamento del bruciore e/o del dolore esofageo associato ai disturbi o malattia da reflusso gastroesofageo. |